𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cisplatin-based (PVB+M) chemotherapy in good-risk and poor-risk nonseminomatous germ cell tumors

✍ Scribed by Dr. Tapan Saikia; Upendra Hegde; Suresh Advani; Gopal Ramakrishnan; Jagdeesh Kulkarni; Prafulla B. Desai

Publisher
John Wiley and Sons
Year
1992
Tongue
English
Weight
313 KB
Volume
51
Category
Article
ISSN
0022-4790

No coin nor oath required. For personal study only.

✦ Synopsis

Twenty-seven patients with metastatic nonseminomatous germ cell tumors were treated with Cisplatin, vinblastine, bleomycin, and low-dose methotrexate (PVB + M) combinations. Patients were divided into good-risk and poor-risk groups. All seven patients (100%) with good-risk factors achieved complete response, and all are alive disease free at a median of 70 months. In the poor-risk group, only 10 of 20 patients (50%) achieved complete response, and seven (35%) are alive disease free at a median of 58 months. Eight patients, 4 in each group, were required to undergo surgery for removal of postchemotherapy residual masses. The results confirm that Cisplatin-based chemotherapy protocols are adequate to cure most patients with good-risk factors, and newer approaches are needed for patients at poor risk.

πŸ“œ SIMILAR VOLUMES

VAB-5 combination chemotherapy in progno
VAB-5 combination chemotherapy in prognostically poor risk patients with germ cell tumors
✍ Davor Vugrin; Willet F. Whitmore; Robert B. Golbey πŸ“‚ Article πŸ“… 1983 πŸ› John Wiley and Sons 🌐 English βš– 429 KB πŸ‘ 2 views

Forty-four patients with nonseminomatous germ cell tumors with "poor prognostic features" were entered on the VAB-5 regimen and 38 are evaluable. VAB-5 represents an intensified version of the VAB-4 protocol. Poor prognostic features were considered to be bulky metastases (>5 cm in diameter), palpab

Serum tumor markers and patient allocati
Serum tumor markers and patient allocation to good-risk and poor-risk clinical trials in patients with germ cell tumors
✍ George J. Bosl; Nancy L. Geller; Dean Bajorin πŸ“‚ Article πŸ“… 1991 πŸ› John Wiley and Sons 🌐 English βš– 552 KB

The allocation of patients with advanced germ cell tumors (GCT) to different treatment programs based on clinical characteristics is standard in the design of clinical trials today. Studies have shown that substantial differences exist between entry criteria and that these differences could influenc

Cisplatin-based chemotherapy after retro
Cisplatin-based chemotherapy after retroperitoneal lymph node dissection in patients with pathological stage II nonseminomatous germ cell tumors
✍ Culine, StΓ©phane; Theodore, Christine; Farhat, Fadi; Bekradda, Mohammed; Terrier πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 384 KB πŸ‘ 1 views

In order to assess the results of cisplatin-based chemotherapy after primary lymph node dissection in patients with pathological stage II nonseminomatous germ cell tumors of the testis, we retrospectively reviewed the longterm outcome of 44 patients who received adjuvant chemotherapy at Institut Gus